"Confounders and Discrepancies: We Need More Rigorous Trials"
Prakash Krishnan, MD, FACC, associate professor of medicine, cardiology, and radiology at the Icahn School of Medicine at Mount Sinai discusses his ILLUMENATE study. According to Dr. Krishnan, “Our primary goal as physicians is to do no harm. Currently we are all reviewing the data and the meta-analysis, and analyzing the conclusions of this study. I am concerned at the mortality discrepancy between the meta-analysis and what was reported individually in each of the randomized, controlled IDE trials: IN.PACT SFA (Medtronic), Lutonix LEVANT 2 (BD), and ILLUMENATE with the Stellarex DCB (Philips).” Dr. Krishnan added, “Another major concern regarding the meta-analysis is the way it was conducted. Some obvious concerns are that the meta-analysis initially included 28 randomized, controlled trials, but the primary conclusions were only based on the three randomized, controlled trials that had five-year data.”
— Prakash Krishnan, MD, FACC, Associate Professor, Medicine, Cardiology, Radiology, Icahn School of Medicine at Mount Sinai, Director, Endovascular Interventions, Cardiac Catheterization Laboratory, The Mount Sinai Hospital, Co-Director, Live Symposium, Complex Coronary and Vascular Cases, Director, Mount Sinai Peripheral Interventions Live Webcast